117m Sn DTPA
Alternative Names: Pentetate 117m Sn; Stanamet; Tin-117m DTPALatest Information Update: 05 Jun 2007
At a glance
- Originator Nonindustrial source
- Developer Bayer Schering Pharma; Nonindustrial source
- Class Analgesics; Radiopharmaceuticals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bone cancer; Cancer pain
Most Recent Events
- 17 Jun 2004 Discontinued - Phase-II for Cancer pain in USA (unspecified route)
- 16 Nov 1999 Diatide has been acquired by Schering AG
- 01 Jul 1999 The US Department of Energy will give Brookhaven National Laboratory US$750,000 over 3 years to develop Stanamet